INVO Fertility Shares Plummet 34% Following 1-for-3 Reverse Split

Introduction

INVO Fertility Inc (NASDAQ: IVF; Korean: 인보 페르틸러티) is a healthcare services company headquartered in Sarasota, Florida. Founded in 2007, the company builds, acquires, and operates fertility clinics and distributes its proprietary INVOcell® medical device, which enables fertilization and early embryo development within the woman’s body through intravaginal culture (IVC).

Corporate Structure and Experience

INVO Fertility employs between 11 and 50 professionals under the leadership of CEO Steven M. Shum. Its principal assets include two dedicated “INVO Centers” offering the IVC procedure and one in vitro fertilization (IVF) clinic in the United States. The company also sells and distributes the INVOcell solution to third-party fertility providers, combining clinical service operations with product licensing.

Fertility clinic by Jonathan Borba

Recent Developments and News

• July 17, 2025: Announced a 1-for-3 reverse stock split effective July 21, 2025, intended to meet NASDAQ’s $1.00 per share minimum bid requirement. Following the split, approximately 928,272 shares will be outstanding, with 1,388,888 authorized.
• October 14, 2025: Filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission to register securities under the Securities Act of 1933.
• October 16, 2025: Closed at $0.9199 per share, representing a decline of 34.29% from the prior session, with a trading volume of 3,573,726 shares.

Financial and Strategic Analysis

For the twelve months ended October 2025, INVO Fertility reported revenue of $6.62 million and a net loss of $10.21 million. Key metrics include:

• Cash and equivalents: $0.55 million
• Total debt/equity ratio: 270.77%
• Price/sales ratio (TTM): 0.01
• Diluted EPS (TTM): –$92.72

The reverse stock split is a measure to maintain compliance with NASDAQ listing standards. With cash resources limited and debt levels elevated, INVO Fertility's strategy involves expanding IVC clinic operations and licensing technology. Future capital raises or strategic partnerships may be necessary to support ongoing operations and growth.

Market Position and Industry Context

INVO Fertility operates within the assisted reproductive technology (ART) industry, positioning INVOcell as a lower-cost alternative to traditional IVF and intrauterine insemination (IUI). The global fertility market continues to grow in response to increasing demand for accessible treatments. Despite its innovative IVC approach, INVO Fertility remains a smaller participant compared to larger clinic networks and established ART equipment manufacturers.

tl;dr

Shares of INVO Fertility fell 34.29% to $0.9199 on October 16, 2025. The company executed a 1-for-3 reverse stock split on July 21, 2025, and filed an S-1 on October 14, 2025, to register securities for future financing. Ensuring NASDAQ compliance and funding clinic and technology expansion will depend on acquiring additional capital and forming partnerships.